Should I buy or sell Edesa Biotech stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Edesa Biotech in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EDSA shares. View EDSA analyst ratings or view top-rated stocks .

What is Edesa Biotech's stock price target for 2024?

2 analysts have issued 1 year target prices for Edesa Biotech's stock. Their EDSA share price targets range from $21.00 to $57.00. On average, they expect the company's stock price to reach $39.00 in the next twelve months. This suggests a possible upside of 796.6% from the stock's current price. View analysts price targets for EDSA or view top-rated stocks among Wall Street analysts .

How have EDSA shares performed in 2024?

Edesa Biotech's stock was trading at $4.57 at the beginning of 2024. Since then, EDSA shares have decreased by 4.8% and is now trading at $4.35. View the best growth stocks for 2024 here .

Are investors shorting Edesa Biotech?

Edesa Biotech saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 19,500 shares, an increase of 10.2% from the March 15th total of 17,700 shares. Based on an average trading volume of 13,800 shares, the short-interest ratio is currently 1.4 days. Approximately 0.8% of the shares of the stock are short sold. View Edesa Biotech's Short Interest .

When is Edesa Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our EDSA earnings forecast .

How were Edesa Biotech's earnings last quarter?

Edesa Biotech, Inc. (NASDAQ:EDSA) posted its quarterly earnings data on Friday, February, 9th. The company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($1.21) by $0.67.

When did Edesa Biotech's stock split?

Shares of Edesa Biotech reverse split on the morning of Wednesday, October 11th 2023. The 1-7 reverse split was announced on Tuesday, October 10th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 10th 2023. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

What other stocks do shareholders of Edesa Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Edesa Biotech investors own include Pfizer (PFE) , AbbVie (ABBV) , VBI Vaccines (VBIV) , Vaxart (VXRT) , Exxon Mobil (XOM) , Anavex Life Sciences (AVXL) , Occidental Petroleum (OXY) , Sorrento Therapeutics (SRNE) , AT&T (T) and Amarin (AMRN) .

How do I buy shares of Edesa Biotech?

Shares of EDSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:EDSA

Edesa Biotech (EDSA) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free EDSA Stock Alerts

$4.35

-0.05 (-1.14%)

(As of 04/18/2024 ET)

Compare

Today's Range: $4.29
▼
$4.44
50-Day Range: $4.06
▼
$5.67
52-Week Range: $2.46
▼
$8.61

Volume: 1,370 shs
Average Volume: 12,837 shs
Market Capitalization: $14.01 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $39.00

Get Edesa Biotech alerts:

Edesa Biotech MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 796.6% Upside
$39.00 Price Target
Short Interest: Healthy
0.83% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$20,000 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($2.32) to ($1.67) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.18 out of 5 stars

Medical Sector

525th out of 918 stocks

Pharmaceutical Preparations Industry

228th out of 402 stocks

3.5

Analyst's Opinion

Consensus Rating
Edesa Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Edesa Biotech has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.83% of the float of Edesa Biotech has been sold short.
Short Interest Ratio / Days to Cover
Edesa Biotech has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Edesa Biotech has recently increased by 10.17%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Edesa Biotech does not currently pay a dividend.
Dividend Growth
Edesa Biotech does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for EDSA.

0.6

News and Social Media Coverage

Search Interest
1 people have searched for EDSA on MarketBeat in the last 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Edesa Biotech insiders have bought more of their company's stock than they have sold. Specifically, they have bought $20,000.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
25.00% of the stock of Edesa Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 5.50% of the stock of Edesa Biotech is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Edesa Biotech are expected to grow in the coming year, from ($2.32) to ($1.67) per share.
Price to Book Value per Share Ratio
Edesa Biotech has a P/B Ratio of 1.86. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Edesa Biotech Stock (NASDAQ:EDSA)

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

EDSA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

EDSA Stock News Headlines

March 26, 2024 | insidertrades.com

Insider Buying: Edesa Biotech, Inc. (NASDAQ:EDSA) CEO Acquires 5,000 Shares of Stock

February 15, 2024 | finance.yahoo.com

EDSA: Development of EB05 in ARDS Continues…

April 18, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

February 14, 2024 | investing.com

Edesa Biotech Inc (EDSA)

February 11, 2024 | benzinga.com

Edesa Biotech Stock (NASDAQ:EDSA) Earnings Dates and Earning Calls

February 9, 2024 | finance.yahoo.com

Edesa Biotech Reports Fiscal 1st Quarter 2024 Results

January 2, 2024 | finance.yahoo.com

EDSA: Updated Phase 3 Protocol for EB05 Trial Approved by Canadian Regulators…

December 15, 2023 | finance.yahoo.com

Edesa Biotech Reports Fiscal Year 2023 Results

April 18, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

December 1, 2023 | benzinga.com

Edesa Biotech Stock (NASDAQ:EDSA) Dividends: History, Yield and Dates

November 12, 2023 | morningstar.com

Edesa Biotech Inc EDSA

November 2, 2023 | msn.com

Edesa Biotech (EDSA) Price Target Increased by 528.00% to 53.38

October 26, 2023 | finance.yahoo.com

Edesa Biotech to Present at Dermatology Drug Development Summit

October 25, 2023 | finance.yahoo.com

Regulators Approve Updated Phase 3 Trial Design for Edesa Biotech’s ARDS Drug

October 19, 2023 | finance.yahoo.com

EDSA: Secures up to CAD$23 Million to Fund Development of EB05…

October 12, 2023 | msn.com

Why Is Infectious Disease Player Edesa Biotech Stock Soaring Today?

October 12, 2023 | finance.yahoo.com

Edesa Biotech to Receive Up To C$23 Million in Funding from Federal Government

October 12, 2023 | finance.yahoo.com

Edesa Biotech Secures $10 Million Credit Facility with Company Founder

October 11, 2023 | seekingalpha.com

Edesa Biotech falls after 1-for-7 reverse stock split announcement

October 10, 2023 | marketwatch.com

Edesa Biotech Falls to 52-Week Low on Reverse Split News

October 10, 2023 | finance.yahoo.com

Edesa Biotech Announces One-for-Seven Reverse Share Split

September 28, 2023 | finance.yahoo.com

Edesa Biotech Publishes Phase 2 Substudy Results of ARDS Drug Candidate

August 16, 2023 | finance.yahoo.com

EDSA: EB05 Inhibits Inflammation Initiated by Multiple Pathogens In Vitro…

August 15, 2023 | msn.com

HC Wainwright & Co. Maintains Edesa Biotech (EDSA) Buy Recommendation

August 9, 2023 | finance.yahoo.com

Edesa Biotech Reports Fiscal Third Quarter 2023 Results

July 27, 2023 | finance.yahoo.com

Edesa Biotech to Participate in Upcoming Canaccord Genuity Growth Conference

June 28, 2023 | msn.com

Edesa Biotech's COVID-19 Candidate Restraints Inflammation From Influenza, Other Pathogens In Preclinical Studies

See More Headlines

Receive EDSA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Edesa Biotech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/09/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 9/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:EDSA
CUSIP: N/A
CIK: 1540159
Web: www.edesabiotech.com
Phone: (289) 800-9600
Fax: 805-488-2889
Employees: 16
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $39.00
High Stock Price Target: $57.00
Low Stock Price Target: $21.00
Potential Upside/Downside: +796.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-8,370,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -103.78%
Return on Assets: -83.85%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.73
Quick Ratio: 2.73

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.34 per share
Price / Book: 1.86

Miscellaneous

Outstanding Shares: 3,220,000
Free Float: 2,412,000
Market Cap: $14.01 million
Optionable: Not Optionable
Beta: 0.32

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Dr. Pardeep Nijhawan FRCPC (Age 53)
M.D., CEO, Company Secretary & Director
Comp: $475.33k
Dr. Michael J. Brooks M.B.A. (Age 46)
Ph.D., President
Comp: $439.27k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

EDSA Stock Analysis - Frequently Asked Questions

Should I buy or sell Edesa Biotech stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Edesa Biotech in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EDSA shares.
View EDSA analyst ratings or view top-rated stocks.
What is Edesa Biotech's stock price target for 2024?: 2 analysts have issued 1 year target prices for Edesa Biotech's stock. Their EDSA share price targets range from $21.00 to $57.00. On average, they expect the company's stock price to reach $39.00 in the next twelve months. This suggests a possible upside of 796.6% from the stock's current price.
View analysts price targets for EDSA or view top-rated stocks among Wall Street analysts.
How have EDSA shares performed in 2024?: Edesa Biotech's stock was trading at $4.57 at the beginning of 2024. Since then, EDSA shares have decreased by 4.8% and is now trading at $4.35.
View the best growth stocks for 2024 here.
Are investors shorting Edesa Biotech?: Edesa Biotech saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 19,500 shares, an increase of 10.2% from the March 15th total of 17,700 shares. Based on an average trading volume of 13,800 shares, the short-interest ratio is currently 1.4 days. Approximately 0.8% of the shares of the stock are short sold.
View Edesa Biotech's Short Interest.
When is Edesa Biotech's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our EDSA earnings forecast.

How were Edesa Biotech's earnings last quarter?: Edesa Biotech, Inc. (NASDAQ:EDSA) posted its quarterly earnings data on Friday, February, 9th. The company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($1.21) by $0.67.
When did Edesa Biotech's stock split?: Shares of Edesa Biotech reverse split on the morning of Wednesday, October 11th 2023. The 1-7 reverse split was announced on Tuesday, October 10th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 10th 2023. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.
What other stocks do shareholders of Edesa Biotech own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Edesa Biotech investors own include Pfizer (PFE), AbbVie (ABBV), VBI Vaccines (VBIV), Vaxart (VXRT), Exxon Mobil (XOM), Anavex Life Sciences (AVXL), Occidental Petroleum (OXY), Sorrento Therapeutics (SRNE), AT&T (T) and Amarin (AMRN).
How do I buy shares of Edesa Biotech?: Shares of EDSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EDSA) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial